Mike, the point would be to continue to develop Ly
Post# of 30028
Posted On: 09/02/2014 11:21:40 PM
Re: MikeChavelle #5419
Mike, the point would be to continue to develop LymPro while generating revenue from selling to the Alzheimer's researchers who are conducting drug trials. The CLIA data will be used to support FDA approval later on. At or near the time FDA approves LymPro, and we tap into the massive revenue stream of $500M to $1B per year, that will be near the point of maximum value for the LymPro asset.
Read up on Lilly's acquisition of Amyvid. We may follow a similar path with LymPro. I'm really thinking along those lines now that Gerald described the acquisition of Avid Radiophamaceuticals in such detail in the call. I would expect any buyout of LymPro to be so large it could fund MANF research on many fronts for many years. Just my thoughts. Only time will reveal how all of this will actually play out, but the possibility is definitely there regarding LymPro and how the company has been restructured as a holding company.
I'm done for the evening... gotta spend some time on my Theory of Computation course.
Read up on Lilly's acquisition of Amyvid. We may follow a similar path with LymPro. I'm really thinking along those lines now that Gerald described the acquisition of Avid Radiophamaceuticals in such detail in the call. I would expect any buyout of LymPro to be so large it could fund MANF research on many fronts for many years. Just my thoughts. Only time will reveal how all of this will actually play out, but the possibility is definitely there regarding LymPro and how the company has been restructured as a holding company.
I'm done for the evening... gotta spend some time on my Theory of Computation course.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼